4.3 Parenteral Admixtures, Reconstitution & Sterile Beyond-Use Dates

Parenteral Admixtures, Reconstitution & Sterile Beyond-Use Dates

Core Principle: Parenteral drug administration bypasses the body's natural cutaneous and gastrointestinal defense barriers, injecting solutions directly into vascular and tissue spaces. This demands absolute sterility, freedom from pyrogenic endotoxins, physicochemical compatibility, and osmotic safety. Pharmacy technicians must master large and small volume parenterals, safely sequence complex electrolytes in Total Parenteral Nutrition (TPN), execute powder reconstitution calculations, and assign scientifically sound Beyond-Use Dates (BUDs) under NAPRA Model Standards.

---

1. Parenteral Admixture Classifications & Intravenous Vehicles

Parenteral preparations are categorized according to their volume, delivery method, and therapeutic intent.

Volume Categories

1. Large Volume Parenterals (LVPs):
   • Sterile solutions intended for intravenous infusion having a volume greater than 100 mL (commonly 250 mL, 500 mL, and 1,000 mL containers).
   • Applications: Fluid resuscitation, maintenance hydration, correction of severe electrolyte disturbances, and continuous drug infusions (e.g., heparin, insulin, morphine infusions).
2. Small Volume Parenterals (SVPs) / IV Piggybacks (IVPBs):
   • Sterile solutions having a volume of 100 mL or less (commonly 50 mL or 100 mL bags, sometimes 25 mL mini-bags).
   • Applications: Intermittent delivery of medications (e.g., intravenous antibiotics, antifungals, antiemetics) infused over 15 to 60 minutes into an established primary LVP infusion line.
3. Intravenous Push (IVP) / Direct Bolus:
   • Small volumes (typically 1 to 10 mL) administered directly into a venous access port over 1 to 5 minutes using a syringe.

Common Base Solutions & Compatibility Profiles

Osmolarity & Route Selection

• Peripheral Line Limit: Peripheral parenteral nutrition is generally kept at or below about 900 mOsm/L. Highly hypertonic fluids irritate small veins and cause thrombophlebitis and extravasation injury.
• Central Line Administration: Concentrated TPN (for example, 20% to 50% dextrose bases) is given through a Central Venous Catheter (CVC) or Peripherally Inserted Central Catheter (PICC) whose tip sits in the superior vena cava, where fast blood flow dilutes it at once. Other hypertonic products follow institutional protocols.

---

2. Total Parenteral Nutrition (TPN) Compounding & Calcium-Phosphate Compatibility

Total Parenteral Nutrition (TPN) is a complex, hypertonic intravenous admixture supplying amino acids, carbohydrates (dextrose), lipids, electrolytes, vitamins, and trace elements to patients unable to absorb nutrition enterally.

Loading diagram...

2-in-1 vs. 3-in-1 (Total Nutrient Admixture, TNA)

• 2-in-1 Formulations: Combine dextrose, amino acids, sterile water, electrolytes, and vitamins into a single container. IV lipid emulsions (IVLE) are infused separately via a secondary co-infusion line. The solution is clear to pale yellow, so crystalline precipitates are easy to see. It is administered through a 0.22-micrometre in-line filter, which removes particulates and precipitates.
• 3-in-1 (TNA) Formulations: Combine dextrose, amino acids, sterile water, electrolytes, vitamins, and lipids into a single container. The resulting mixture is an opaque, milky-white emulsion. The opacity obscures subtle crystalline precipitates. TNAs must be infused through a 1.2-micrometer in-line filter (a 0.22-μm filter would strip out lipid emulsion droplets, clogging the filter and breaking the emulsion).

The Calcium-Phosphate Precipitation Disaster

The most critical chemical incompatibility in parenteral compounding occurs between calcium cations (Ca²⁺) and dibasic phosphate anions (HPO₄²⁻). They combine to form calcium phosphate (CaHPO₄), an insoluble crystalline salt that causes fatal microvascular pulmonary emboli when infused.

Critical Sequencing & Prevention Rules

1. Phosphate Added First: Always add phosphate salts (potassium phosphate or sodium phosphate) early in the compounding sequence, heavily diluted in the amino acid and dextrose solution.
2. Calcium Added Last: Add calcium near the end of compounding, when the bag is at or near its final maximum volume dilution.
3. Use Calcium Gluconate (Never Calcium Chloride): Calcium gluconate is an organic salt that dissociates very slowly in solution, releasing fewer free Ca²⁺ ions. Calcium chloride is an inorganic salt that dissociates completely and rapidly, dramatically increasing precipitation risk. In TPN compounding, calcium gluconate is always preferred.
4. Amino Acid Concentration & Acidic pH: Higher amino acid concentrations provide a buffering effect that maintains an acidic pH (below 6.0). In an acidic environment, phosphate exists predominantly as the monobasic ion (H₂PO₄⁻), which forms highly soluble salts with calcium. In neutral or alkaline solutions, phosphate shifts to the dibasic form (HPO₄²⁻), precipitating readily.
5. Lipids Added Last: High concentrations of divalent and trivalent cations (Ca²⁺, Mg²⁺) neutralize the repulsive electrostatic charges on lipid droplet surfaces, leading to lipid coalescence, oil layer formation ("cracking"), and emulsion breakdown. Lipids must always be incorporated last, after all other components are diluted.

---

3. Lyophilized Powder Reconstitution & Mathematical Calculations

Many parenteral medications (e.g., cefazolin, ampicillin, vancomycin) are chemically unstable in aqueous solution and are manufactured as dry lyophilized powders. Reconstitution requires sterile diluent addition and precise calculation of powder displacement volume.

The Principle of Powder Displacement

When a dry powder dissolves in a liquid diluent, the powder particles occupy physical space, causing the final reconstituted volume to be greater than the volume of liquid diluent added:

• Final Reconstituted Volume = Volume of Diluent Added + Powder Displacement Volume
• Powder Displacement Volume = Final Reconstituted Volume - Volume of Diluent Added

Step-by-Step Reconstitution Calculation

Clinical Scenario: A pharmacy technician must prepare a pediatric dose of 150 mg of cefazolin. The manufacturer's label on a 1 g cefazolin vial states: "Reconstitute with 2.5 mL of Sterile Water for Injection to yield a concentration of 330 mg/mL."

1. Calculate Total Reconstituted Volume: $$\text{Total Volume} = \frac{1,000\text{ mg}}{330\text{ mg/mL}} = 3.03\text{ mL}$$
2. Calculate Powder Displacement Volume: $$\text{Displacement Volume} = 3.03\text{ mL} - 2.50\text{ mL} = 0.53\text{ mL}$$ The 1 g of dry cefazolin powder occupies 0.53 mL of space.
3. Calculate Volume to Withdraw for the Ordered Dose (150 mg): $$\text{Volume to Withdraw} = \frac{150\text{ mg}}{330\text{ mg/mL}} = 0.45\text{ mL}$$

Diluent Selection & Neonatal Contraindications

• Sterile Water for Injection (SWFI): Sterile, non-pyrogenic, hypotonic water containing no antimicrobial preservatives. It must never be injected IV directly without solutes (causes massive intravascular hemolysis).
• Bacteriostatic Water for Injection (BWFI): Contains an antimicrobial preservative (typically 0.9% benzyl alcohol). Facilitates multi-dose vial entry.
• THE BENZYL ALCOHOL CONTRAINDICATION IN NEONATES: Bacteriostatic diluents containing benzyl alcohol are strictly contraindicated in neonates and low-birth-weight infants (< 28 days of age). Neonates have immature liver and kidney enzyme systems unable to metabolize benzyl alcohol, leading to accumulation, severe metabolic acidosis, central nervous system depression, seizures, and respiratory collapse known as "Gasping Syndrome," which is frequently fatal. BWFI is also strictly contraindicated for epidural or intrathecal administrations due to neurotoxicity.

---

4. Specialized Sterile Manipulation Techniques

Coring Prevention When Puncturing Vials

Coring occurs when the sharp hollow needle tip shears a cylindrical plug of rubber from the vial stopper, dropping particulate rubber debris into the sterile drug solution.

• Technique: Place the vial on a flat surface. Position the needle with the bevel facing upward at a 45-degree angle to the stopper surface. Push the needle point forward into the rubber stopper while simultaneously rotating the syringe and needle upright to a 90-degree angle. The heel of the bevel enters the exact puncture hole made by the point, preventing rubber cutting.

Loading diagram...

Glass Ampoule Manipulation & The Single-Filtration Rule

Glass ampoules are hermetically sealed, all-glass containers.

1. Opening: Tap the head of the ampoule to displace trapped liquid down into the body. Wipe the neck with a sterile 70% IPA swab and allow to dry. Wrap a sterile gauze pad or alcohol swab around the neck and snap the top cleanly away from the HEPA filter face.
2. Filtration Rule: Breaking glass generates hundreds of microscopic glass shards that fall into the liquid. A 5-micrometer filter needle (or filter straw) must be used to withdraw the solution from the ampoule.
3. THE SINGLE-FILTRATION MANDATE: After withdrawing the liquid through the 5-micron filter needle, the technician must detach and discard the filter needle and attach a standard sterile hypodermic needle before injecting the medication into the IV bag. If the filter needle is used to inject into the bag, the trapped glass particles trapped on the filter mesh are flushed directly into the IV admixture. Never filter twice in the same direction or use a filter needle for injection.

---

5. Sterile Beyond-Use Dating (BUD) under NAPRA

NAPRA's Model Standards for Pharmacy Compounding of Non-hazardous Sterile Preparations assign BUDs by risk of microbial contamination. Administration must begin before the BUD passes.

NAPRA Contamination Risk Levels (Table 6)

• Low risk: Up to 3 sterile units; no more than 2 septum punctures per sterile unit; simple aseptic transfer; a patient-specific dose.
• Medium risk: 4 or more sterile units, complex manipulations, prolonged preparation time, or batch preparation (more than one unit of the same composition in a session).
• High risk: Non-sterile ingredients or equipment used before terminal sterilization, water-containing non-sterile preparations held more than 6 hours before sterilization, or improper garbing or gloving.

NAPRA BUDs Without Sterility Testing (Table 7)

High-risk preparations must always be sterilized. NAPRA requires sterility and bacterial endotoxin testing for high-risk batches of more than 25 identical units, among other situations.

Shorter Limits (Table 8)

Exam trap: US USP <797> (2023) uses "Category 1/2/3" CSPs, with 12-hour/24-hour limits for Category 1. Those are not the NAPRA numbers. For Canadian practice, learn the risk levels and times above.

The Absolute Manufacturer Ceiling

The assigned BUD can never exceed the shortest expiry date of any ingredient or container used in the admixture. If a low-risk preparation qualifies for 14 days refrigerated but the diluent bag expires in 3 days, the BUD is capped at 3 days. Use the manufacturer's stability data for reconstituted or diluted products when it is shorter.

---

6. Quality Assurance, Visual Inspection & Labeling

Every sterile preparation must undergo multi-parameter verification by a registered pharmacy technician before release.

Visual Inspection Against Black and White Backgrounds

• Black Background: Used to illuminate light-colored, white, or translucent particulates, crystalline precipitates (e.g., calcium phosphate), and container glass fractures.
• White Background: Used to detect dark or colored particulates, rubber cores, fibers, and liquid discoloration.
• Container Integrity: Gently squeeze IV bags to verify seam integrity and detect micro-punctures or leakage around ports.

Mandatory Label Requirements

• Patient full name, identification number, and nursing unit/bed.
• Active drug name(s), metric strength, and total dose added.
• Vehicle solution name, starting volume, and final total volume.
• Exact rate of infusion (mL/hr) or duration of infusion.
• Assigned Beyond-Use Date (date and exact time of day).
• Mandatory storage conditions (e.g., "Refrigerate (2°C to 8°C)", "Do Not Freeze").
• Compounding technician and verifying pharmacist initials.
• Appropriate auxiliary labels (e.g., "Protect from Light", "Chemotherapy - Handle with Care", "Filter Required").